Comparison of uterine malignancies that develop during and following tamoxifen therapy

Gynecologic Oncology

Volumn 101, Issue 2, 2006, Pages 322-326

  Ferguson, Sarah E ^a   Soslow, Robert A ^a   Amsterdam, Alison ^a   Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Endometrial cancer; High grade histology; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADENOCARCINOMA; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BODY MASS; BREAST CANCER; CANCER CENTER; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RISK; CANCER STAGING; CARCINOSARCOMA; CONTROLLED STUDY; DRUG INDUCED CANCER; EARLY DIAGNOSIS; ENDOMETRIOID CARCINOMA; FEMALE; HUMAN; HUMAN TISSUE; LEIOMYOSARCOMA; MAJOR CLINICAL STUDY; MEDICAL RECORD REVIEW; PARITY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; UTERUS CANCER;

AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; FEMALE; HUMANS; MIDDLE AGED; RETROSPECTIVE STUDIES; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 33646410147     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.10.026     Document Type: Article

References (26)

1. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351 (1998) 1451-1467
2. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339 (1992) 71-85
3. Early Breast Cancer Trialists' Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365 (2005) 1687-1717
4. Fisher B., Costantino J.P., Wickerham D.L., et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl. Cancer Inst. 90 (1998) 1371-1388
5. Fisher B., Costantino J.P., Redmond C.K., Fisher E.R., Wickerham D.L., and Cronin W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 86 (1994) 527-537
6. Wickerham D.L., Fisher B., Wolmark N., et al. Association of tamoxifen and uterine sarcoma. J. Clin. Oncol. 20 (2002) 2758-2760
7. Bernstein L., Deapen D., Cerhan J.R., et al. Tamoxifen therapy for breast cancer and endometrial cancer risk. J. Natl. Cancer Inst. 91 (1999) 1654-1662
8. Bergman L., Beelen M.L., Gallee M.P., Hollema H., Benraadt J., and van Leeuwen F.E. Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of liver and endometrial cancer risk following tamoxifen. Lancet 356 (2000) 881-887
9. Mignotte H., Lasset C., Bonadona V., et al. Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Federation Nationale des Centres de Lutte Contre le Cancer (FNCLCC). Int. J. Cancer 76 (1998) 325-330
10. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., and Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J. Natl. Cancer Inst. 87 (1995) 645-6451
11. Kurman R.J., Zaino R.J., and Norris H.J. Endometrial carcinoma. In: Kurman R.J. (Ed). Blaustein's Pathology of the Female Genital Tract. Third ed. (1994), Springer, New York 439-486
12. Barakat R.R., Wong G., Curtin J.P., Vlamis V., and Hoskins W.J. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol. Oncol. 55 (1994) 164-168
13. Magriples U., Naftolin F., Schwartz P.E., and Carcangiu M.L. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J. Clin. Oncol. 11 (1993) 485-490
14. Creasman W.T. New gynecologic cancer staging. Obstet. Gynecol. 75 (1990) 287-288
15. Singletary S.E., Allred C., Ashley P., et al. Staging system for breast cancer: revisions for the 6th edition of the AJCC Cancer Staging Manual. Surg. Clin. North Am. 83 (2003) 803-819
16. World Health Organization: tumours of the breast and female genital organs (2003), International Agency for Research in Cancer, Lyon
17. Hachisuga T., Saito T., Kigawa J., et al. Clinicopathologic study of 56 patients with endometrial cancer during or after adjuvant tamoxifen use for their breast cancers. Gynecol. Oncol. 95 (2004) 139-144
18. Creutzberg C.L., van Putten W.L., Koper P.C., et al. Surgery and postoperative radiotherapy versus surgery alone for patients with stage-1 endometrial carcinoma: multicentre randomised trial. PORTEC Study Group. Post Operative Radiation Therapy in Endometrial Carcinoma. Lancet 355 (2000) 1404-1411
19. Alektiar K.M., Venkatraman E., Abu-Rustum N., and Barakat R.R. Is endometrial carcinoma intrinsically more aggressive in elderly patients?. Cancer 98 (2003) 2368-2377
20. Chalas E., Costantino J.P., Wickerham D.L., et al. Benign gynecologic conditions among participants in the Breast Cancer Prevention Trial. Am. J. Obstet. Gynecol. 192 (2005) 1230-1237
21. Ferguson S.E., Olshen A.B., Viale A., Awtrey C.S., Barakat R.R., and Boyd J. Gene expression profiling of tamoxifen-associated uterine cancers: evidence for two molecular classes of endometrial carcinoma. Gynecol. Oncol. 92 (2004) 719-725
22. Prasad M., Wang H., Douglas W., Barakat R.R., and Ellenson L.H. Molecular genetic characterization of tamoxifen-associated endometrial cancer. Gynecol. Oncol. 96 (2005) 25-31
23. Kohler M.F., Carney P., Dodge R., et al. p53 overexpression in advanced-stage endometrial adenocarcinoma. Am. J. Obstet. Gynecol. 175 (1996) 1246-1252
24. Inoue M., Okayama A., Fujita M., et al. Clinicopathological characteristics of p53 overexpression in endometrial cancers. Int. J. Cancer 58 (1994) 14-19
25. Hetzel D.J., Wilson T.O., Keeney G.L., Roche P.C., Cha S.S., and Podratz K.C. HER-2/neu expression: a major prognostic factor in endometrial cancer. Gynecol. Oncol. 47 (1992) 179-185
26. Barakat R.R., Gilewski T.A., Almadrones L., et al. Effect of adjuvant tamoxifen on the endometrium in women with breast cancer: a prospective study using office endometrial biopsy. J. Clin. Oncol. 18 (2000) 3459-3463